InnovaCare Health Thrives Further Under Penelope Kokkinides and Rick Shinto

It takes a lot of effort to build a healthcare system and the government has shown commitment in developing a reliable system where citizens are able to access vital services through Medicare plans. The introduction of Medicare and Medicaid programs opened a new chapter in the administration of healthcare services as it offered private healthcare companies a chance to venture into healthcare to provide better healthcare choices to people in various regions.

Among companies that have been supporting the implementation of these programs is InnovaCare Health, which is based in Puerto Rico. InnovaCare Health has been delivering healthcare solutions to users of Medicare by developing reliable plans that have helped the company to stand out in the market. Part of the great performance that has been witnessed at the company in the last five years is attributed to the structural changes that were made to introduce better technological features.

Some of these technologies that were introduced include the development of a better service delivery system that is focused on efficiency and cost effectiveness. The benefits of cost saving that were achieved after the system was installed were transferred to users of various managed healthcare services in the form of cheaper rates. Also top in the reasons InnovaCare Health has been on a trend of growth is that the company embraced new leadership within the last five years, an action that introduced better ideas that later shaped the company towards attaining better performance. Contact details available at Manta.com

Rick Shinto

Rick Shinto currently works as the President and CEO of InnovaCare, Inc. He, before moving to InnovaCare Inc., worked as the President and CEO of Aveta from 2008 until the time the company was sold in 2012. He was also a member of the management team and a key decision maker, who allowed the company to build strong structures of leadership and operations. With more than 20 years experience in operational and clinical healthcare, Rick Shinto proposed useful changes and ideas that portrayed InnovCare Health as a dedicated managed healthcare services provider. He also worked as the Vice President of the Medical Management subsidiary of MedPartners between 1996 and 1997.

Penelope Kokkinides

Penelope Kokkinides, the chief administrative officer of InnovaCare Inc., is a professional whose experience with government programs (Medicaid and Medicare) allowed her to bring transformation to InnovaCare Health that saw the service delivery of the company get better to the advantage of users. She also headed Aveta as CEO and was deputy CEO at the time Rick Shinto held the mantle.

Read more about Innovacare at Crunchbase

Mikhail Blagosklonny – the undisputed Oncologist

Mr. Mikhail Blagosklonny is an undisputed scientist and a professor of oncology who currently works at RPCI (Roswell Park Cancer Institute). He earned both his master degree in internal medicine and Ph.D. in cardiology and experimental medicine from First Pavlov State Medical University. Before joining Roswell Park Cancer Institute, Mikhail was an associate professor at the New York Medical College. Furthermore, Mikhail worked as a scientist at the Ordway Research Institute, where most of his research were focusing on cancer treatment, anti-aging drugs, aging mechanism, and cancer therapies. Perhaps, Blagosklonny is a passionate advocate of the cancer drug known as Rapamycin. He even developed a hypothesis on the role of TOR signaling in aging and cancer treatment. According to the hypothesis, Rapamycin drug can prolong the life of a human being.

Mikhail Blagosklonny serves as a chief editor to several publications such as Cell Cycle and Oncotarget. He also works as an associate editor of the editorial board of Cancer Therapy and Biology. He understands that it is not a miracle to have a society that is free from aging and cancer effects. Because of this reason, Mikhail has dedicated most of his time in conducting more research in oncology study. In addition to his hypothesis, Blagosklonny zeroes in cellular biology, molecular biology, tumor suppressors, clinical investigation, ontogenesis, and anti-cancer therapeutics. Also, Mikhail has made a lot of contributions to the science journals. He believes that through journals, people can be aware of the things that are happening in their life. Mr. Mikhail Blagosklonny has written more than 300 articles. Most of his publications are about cell cyclotherapy, aging hyperfunction, and chemotherapeutic engineering.

Visit ResearchGate.Net to know more about Mikhail’s latest work.